NCT01781871View on ClinicalTrials.gov

Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions
Kidney TransplantationLiver Transplantation
Interventions
BIOLOGICAL

Prevenar13

Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.

BIOLOGICAL

Pneumovax

0.5ml Pneumovax injected intramuscularly at day 1.

Trial Locations (2)

33521

Heikki Saha, Tampere

00029

Helsinki University Central Hospital, Helsinki

All Listed Sponsors
collaborator

Tampere University Hospital

OTHER

lead

Helsinki University Central Hospital

OTHER

NCT01781871 - Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients | Biotech Hunter | Biotech Hunter